美好醫療(301363.SZ):目前階段公司在機器人領域產生的收入規模還比較小
格隆匯3月14日丨美好醫療(301363.SZ)在投資者互動平臺表示,關於機器人的問題,公司憑藉在液態和固態硅膠製造領域領先的技術水平,正積極探索硅膠材料及工藝在機器人等新興領域的應用。但目前階段公司在機器人領域產生的收入規模還比較小,敬請廣大投資者注意相關投資風險。 關於乾眼症治療儀的問題,公司將緊密追蹤醫療器械行業的創新發展趨勢,不斷開拓血糖管理、體外診斷、心血管、眼科、外科等各細分領域的業務機會。目前眼科相關的業務收入規模還比較小。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.